Results 221 to 230 of about 67,152 (253)
Some of the next articles are maybe not open access.
2015
Direct oral anticoagulants (DOACs) are rapidly changing the way we think about selecting, treating, and monitoring patients in need of anticoagulation. These agents may be used for either treatment or prophylaxis of systemic embolism and have been compared to vitamin K antagonist (e.g., warfarin) for many of the same indications.
openaire +2 more sources
Direct oral anticoagulants (DOACs) are rapidly changing the way we think about selecting, treating, and monitoring patients in need of anticoagulation. These agents may be used for either treatment or prophylaxis of systemic embolism and have been compared to vitamin K antagonist (e.g., warfarin) for many of the same indications.
openaire +2 more sources
Direct oral anticoagulants in hypercoagulable states
Journal of Thrombosis and Thrombolysis, 2016Direct oral anticoagulants have been shown safe and effective in the treatment of pulmonary emboli and deep vein thrombi. Their role in the treatment of patients with hypercoagulability is uncertain. We designed a retrospective exploratory analysis of all patients with definite heparin induced thrombocytopenia (HIT) and antiphospholipid syndrome (APS ...
Paul R. Kunk +4 more
openaire +3 more sources
2018
Four direct oral anticoagulants (DOACs)—dabigatran, a direct thrombin inhibitor, and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban—have been approved for prevention of stroke in non-valvular atrial fibrillation and treatment of venous thromboembolism (VTE).
openaire +2 more sources
Four direct oral anticoagulants (DOACs)—dabigatran, a direct thrombin inhibitor, and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban—have been approved for prevention of stroke in non-valvular atrial fibrillation and treatment of venous thromboembolism (VTE).
openaire +2 more sources
Antikoagulation – direkte orale Antikoagulanzien
Der Internist, 2017Since direct oral anticoagulants (DOAC) have become available, use of anticoagulant treatment has become easier and safer-for patients suffering from thromboembolic diseases as well as for patients with atrial fibrillation: Because of constant bioavailability, fixed dose regimen treatment is possible, monitoring not necessary and severe bleeding ...
openaire +3 more sources
The promise of novel direct oral anticoagulants
Best Practice & Research Clinical Haematology, 2012The standard effective treatment of venous and arterial thromboembolism includes unfractionated and low-molecular weight heparin as well as warfarin, which have major disadvantages. In recent years, new anticoagulants have been developed in an attempt to overcome the known limitations of established treatment and develop improved therapies.
Ron Hoffman +3 more
openaire +2 more sources
Direct Oral Anticoagulants in Atrial Fibrillation
Seminars in Hematology, 2014Atrial fibrillation (AF), the most frequent sustained arrhythmia, is associated with an increased risk of thromboembolic events. The risk of stroke depends on risk factors such as age, hypertension, heart failure, and vascular disease. Thus, antithrombotic therapy is a cornerstone in the management of AF.
David Hürlimann, Georg Noll, Sarah Noll
openaire +3 more sources
Direct oral anticoagulants today
Medicina Clínica (English Edition), 2021Carlos Escobar Cervantes +1 more
openaire +2 more sources
Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants
The Lancet HaematologyOver the last decade, the advent of direct oral anticoagulants (DOACs) has rapidly changed the landscape of anticoagulation. In the early 2010s, DOACs became widely available for stroke prevention in atrial fibrillation and the treatment of venous thromboembolism.
Ageno W. +4 more
openaire +3 more sources
Reversal of direct oral anticoagulants
British Journal of Hospital Medicine, 2018Lucy-Anne Frank +2 more
openaire +3 more sources